178984-56-0

Basic information

• Product Name: 7-BENZYLOXY-4-CHLOROQUINOLINE
• Synonyms: 7-BENZYLOXY-4-CHLOROQUINOLINE;4-chloro-7-benzoxyquinoline;4-chloro-7-(phenylMethoxy;4-chloro-7-phenoxy-quinoline
• CAS NO: 178984-56-0
• Molecular Formula: C₁₆H₁₂ClNO
• Molecular Weight: 269.73
• Mol File: 178984-56-0.mol

Chemical Properties

• Boiling Point: 414.058 °C at 760 mmHg
• Flash Point: 204.215 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.86±0.27(Predicted)
• CAS DataBase Reference: 7-BENZYLOXY-4-CHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BENZYLOXY-4-CHLOROQUINOLINE(178984-56-0)
• EPA Substance Registry System: 7-BENZYLOXY-4-CHLOROQUINOLINE(178984-56-0)

Safety Data

• Hazardous Substances Data: 178984-56-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Benzyloxy-4-chloroquinoline is used as an intermediate in the synthesis of antimalarial drugs for its potential to contribute to the development of treatments against malaria.
7-Benzyloxy-4-chloroquinoline is also used as an intermediate in the synthesis of antiviral drugs, indicating its potential role in creating medications to combat viral infections.
Used in Antimicrobial Applications:
7-Benzyloxy-4-chloroquinoline is used as an antimicrobial agent, leveraging its ability to inhibit the growth of microorganisms, which can be beneficial in various medical and healthcare settings.
Used in Antifungal Applications:
7-Benzyloxy-4-chloroquinoline is utilized as an antifungal agent, helping to prevent and treat fungal infections, which is particularly important in maintaining skin health and treating conditions caused by fungal overgrowth.
Further research into the properties and potential uses of 7-benzyloxy-4-chloroquinoline is ongoing, with the aim of expanding its applications and understanding its full therapeutic potential.

InChI:InChI=1/C16H12ClNO/c17-15-8-9-18-16-10-13(6-7-14(15)16)19-11-12-4-2-1-3-5-12/h1-10H,11H2

Upstream product

• 71083-05-1 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 56881-19-7 Diethyl 2-<(3-methoxyphenylamino)methylene>malonate 
• 536-90-3 m-Anisidine 
• 190516-85-9 7-methoxy-4(1H)-oxoquinoline 
• 68500-37-8 4-chloro-7-methoxyquinoline 
• 181950-57-2 4-chloro-7-hydroxyquinoline 
• 100-39-0 benzyl bromide 
• 749922-34-7 7-(benzyloxy)quinolin-4-ol 
• 909345-85-3 5-((3-(benzyloxy)phenylamino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 749922-34-7 7-(benzyloxy)quinolin-4(1H)-one 
• 1484-26-0 3-(benzyloxy)aniline 

Downstream Products

• 1221443-46-4 N-(3-fluoro-4-(7-hydroxyquinolin-4-yloxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394820-98-4 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol 
• 1394820-99-5 1-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-70-2 (R)-N-(3-fluoro-4-((7-(2-hydroxypropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-01-2 4-(4-amino-2-fluorophenoxy)quinolin-7-ol 
• 1394820-83-7 N-(4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-03-4 4-(4-nitrophenoxy)quinolin-7-ol 
• 1394821-04-5 2-methyl-1-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)propan-2-ol 
• 1394821-05-6 1-((4-(4-aminophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-85-9 N-(4-((7-(2-hydroxyethoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-06-7 2-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)ethanol 
• 1394821-07-8 2-((4-(4-aminophenoxy)quinolin-7-yl)oxy)ethanol 
• 1394820-87-1 (R)-N-(4-((7-(2-hydroxypropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-08-9 (R)-1-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)propan-2-ol 

Relevant articles and documents

Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents

A series of new quinoline derivatives was designed, synthesized and evaluated as potential antitumor agents. The results indicated that most compounds exhibited potent antiproliferative activity, and 7-(4-fluorobenzyloxy)–N-(2-(dimethylamino)- ethyl)quinolin-4-amine 10g was found to be the most potent antiproliferative agent against human tumor cell lines with an IC50 value of less than 1.0 μM. Preliminary structure-activity relationships analysis suggested that (1) the large and bulky alkoxy substituent in position-7 might be a beneficial pharmacophoric group for antiproliferative activity; (2) the amino side chain substituents in position-4 facilitated the antiproliferative activity of this class of compounds; and (3) the length of the alkylamino side chain moiety affected the antiproliferative potency, with two CH2 units being the most favorable. Further investigation of the mechanism of action of this class of compounds demonstrated that the representative compound 10g triggered p53/Bax-dependent colorectal cancer cell apoptosis by activating p53 transcriptional activity. Moreover, the results showed that compound 10g effectively inhibited tumor growth in a colorectal cancer xenograft model in nude mice. Thus, these quinoline derivatives might serve as candidates for the development of new antitumor drugs.

COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

For antibacterial chlorine oxygen kui derivatives

The invention relates to an oxo-quinoline derivative with activity of resisting bacterial infection relevant diseases such as helicobacter pylori (Hp) infection disease. The invention specifically relates to a compound as shown in formula I in the specification, and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is selected from hydrogen, -C alkyl, -C alkenyl, -C alkynyl, or -C alkyl-phenyl, and the alkyl, alkenyl, alkynyl and phenyl can be randomly substituted by halogen, nitro, cyan, hydroxyl, -C alkoxy and phenyl; R is selected from hydrogen, -CONHR and -COOR, R and R are independently selected from -C alkyl and -C alkyl amino, and the amino is randomly substituted by one to two -C alkyls; R is selected from halogen, -C alkoxy, morpholinyl or piperazinyl.

With anti-tumor activity of chlorine oxygen kui derivatives

The invention relates to a chloroxoquinoline derivatives with anti-tumor activity and specifically relates to compounds of a formula I as shown in the specification and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein R1 is selected from hydrogen, -C1-6 alkyl, -C2-6 alkenyl, -C2-6 alkynyl and -C1-6 alkyl-phenyl, and the alkyl, the alkenyl, the alkynyl and the phenyl can be optionally substituted by halogens, nitryl, cyan, hydroxyl, -C1-6 alkoxy and phenyl; R3 is selected from hydrogen, -CONHR31 and -COOR32, the R31 and the R32 are independently selected from -C1-6 alkyl and -C1-6 alkylamino, respectively, and the amino can be optionally substituted by 1 to 2 -C1-6 alkyls; R7 is selected from halogens, -C1-6 alkoxy, morpholinyl and piperazine; the formula I is as shown in the specification.

BMP INHIBITORS AND METHODS OF USE THEREOF

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

NOVEL QUINOLINE DERIVATIVES

The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).